Dissatisfaction in Atopic Dermatitis Treatment Revealed; Clear Opportunities for New Entrants

PR60730

NUREMBERG, Germany, June 9 / PRN=KYODO JBN / --

    - Over four out of 10 physicians and six out of 10 patients are not

satisfied with the level of control achieved for moderate to severe adult

patients treated with high potency topical steroids.

    - 91 percent of moderate to severe adults receiving high potency topical

steroids are expected to repeat this same treatment.

    Latest results from GfK Disease Atlas

[https://www.gfk.com/Industries/health/Pages/Disease-Atlas.aspx ], a real-world

evidence program linking physician- and patient-reported treatment data,

reveals major gaps in satisfaction levels for the treatment of atopic

dermatitis.

    The international survey of physicians and patients shows that 43 percent

of physicians treating moderate to severe adult atopic dermatitis patients with

high potency topical steroids are not satisfied with the level of control

achieved. And dissatisfaction among the patients themselves stands at 66

percent.

    Worse yet, patients expect to be dissatisfied: 92 percent agree that their

doctor explained to them what to expect from this treatment.

    Results also reveal repeated use of high potency topical steroids among

moderate to severe adult patients, with 91 percent receiving this therapy set

to repeat this treatment, according to the prescribing physician.

    These same patterns are seen with another common therapy for moderate to

severe atopic dermatitis: oral steroids, with similar high dissatisfaction

levels amongst physicians and patients, and similar repeat use.

    "The lack of new therapies for atopic dermatitis means that patients are

often cycled through the same old treatment options, such as topical steroids

and oral steroids," said Alison Rose, Immunology & Dermatology Therapy Director

at GfK. "But the low satisfaction level with these habitual treatments that we

are seeing among both doctors and patients indicates huge potential for any

players entering this market with new therapy options."

    GfK will be sharing further insights on dermatology at the World Congress

of Dermatology June 8-13 in Vancouver, Canada, via a Feature Poster on

"Analysis of physician and patient perceptions of chronic hand eczema - a

global survey."

    About the research survey

    GfK Disease Atlas

[https://www.gfk.com/Industries/health/Pages/Disease-Atlas.aspx ] for atopic

dermatitis covers eight countries, delivering patient level data from over

4,000 pediatric and adult atopic dermatitis patients, together with insights

from over 800 physicians. Similar programs are also available for acne,

psoriasis or rheumatology.

    For more information, please visit:

https://www.gfk.com/Industries/health/Pages/Disease-Atlas.aspx

    Contact: Ben Walton, ben.walton@gfk.com, +44-7919-300952

    Source: GfK